BioSpace News Archive

Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne ® CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008.

TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Co-Principal Executive Officers.

Corindus , A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today it presented the results of a first-of-its-kind study demonstrating the safety and effectiveness of robotic-assisted neurovascular aneurysm embolization using the CorPath GRX Neurovascular System.

Spotlight Therapeutics, Inc. today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer.

Fore Biotherapeutics announced the presentation of new data demonstrating that FORE8394, a next-generation BRAF inhibitor, provides evidence of durable anti-tumor activity and patient benefit in BRAF-mutated (V600+) cancers.

Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival (OS) compared to trifluridine/tipiracil alone in a Phase III clinical trial of participants with refractory metastatic colorectal cancer (mCRC) following two chemotherapy regimens.

Science 37 Holdings, Inc. today announced that Michael Shipton has been appointed Chief Commercial Officer to lead business development, strategic solutions, sales operations, and strategic pricing, effective today.

Braxia Scientific Corp. is pleased to announce it has successfully launched KetaMD in Florida.

Arbor Biotechnologies announced that Fierce Biotech has named it as one of 2022’s “Fierce 15” biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC).